Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Botulinum toxin A - Merz Pharma

Next Previous
Drug Profile

Botulinum toxin A - Merz Pharma

Alternative Names: Bocouture; Incobotulinum toxin A; NT 201L; NT-201; Vibe/Xeomin®200U; Vibe/Xeomin®300U; Vibe/Xeomin®600U; ViXe; Xeomeen; XEOMIN; Xeomin; Xeomin cosmetic; Zeomaine

Latest Information Update: 01 Sep 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator BIOTECON Therapeutics
  • Developer Merz Aesthetics; Merz Pharma; Merz Pharmaceuticals GmbH; Vensica Therapeutics; Yale University
  • Class Analgesics; Anti-inflammatories; Antiarrhythmics; Antidepressants; Antimigraines; Antipruritics; Antispasmodics; Bacterial proteins; Bacterial toxins; Botulinum toxins; Eye disorder therapies; Foot disorder therapies; Muscle relaxants; Recombinant proteins; Skin disorder therapies; Urologics; Vascular disorder therapies
  • Mechanism of Action Acetylcholine inhibitors; Glutamate antagonists; Membrane transport protein modulators; Neuromuscular blocking agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Blepharospasm; Dystonia; Glabellar lines; Muscle spasticity; Sialorrhoea; Torticollis
  • Phase III Atrial fibrillation; Facial wrinkles; Migraine
  • Phase II Alopecia; Essential tremor; Neuropathic pain; Overactive bladder; Skin aging; Trigeminal neuralgia
  • Phase I Unspecified
  • Preclinical Interstitial cystitis; Neurogenic bladder
  • No development reported Pain
  • Discontinued Cancer pain

Most Recent Events

  • 25 Aug 2025 Phase-III clinical trials in Migraine (Prevention) in USA (Parenteral) (NCT07018713)
  • 25 Aug 2025 Merz Pharmaceuticals initiates enrolment in the phase III MINT-E trial for Migraine (Prevention) in USA (Parenteral) (NCT07018700)
  • 25 Aug 2025 Merz Pharma plans a phase III PLATINUM US trial for Unspecified in USA (IM), in August 2025 (NCT07122193)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top